Musashi‐1 Drives Radioresistance and Stemness in Head and Neck Squamous Cell Carcinoma via a Radioresistant FaDu Model Authors: Na‐Eun Kang, Chan‐Woong Jung, Yun‐Ju Kim, Sung‐Gil Chi, Jeong‐Yub Kim, Myung‐Jin Park Published: 2026 ABSTRACT ABSTRACTHead and neck squamous cell carcinoma (HNSCC) is frequently managed with radiotherapy, but the emergence of radioresistant cancer cells with cancer stem cell (CSC) properties remains a major clinical obstacle. Here, we established a radioresistant FaDu cell line (F‐IRR) by repeated fractionated irradiation to investigate the molecular basis of radiation resistance in HNSCC. Irradiated colony‐forming assays confirmed the radioresistant phenotype of F‐IRR cells. Although F‐IRR cells proliferated more slowly than parental cells, they exhibited markedly enhanced CSC activity, as demonstrated by sphere formation, limiting dilution, and soft agar assays. Among multiple stem cell‐associated markers, Musashi‐1 (MSI1)—an ribonucleic acid (RNA)‐binding protein with established roles in CSC maintenance—was the most prominently upregulated, as confirmed by western blot, reverse transcription‐polymerase chain reaction (RT‐PCR), and immunocytochemistry. Functional studies demonstrated that siRNA‐mediated knockdown of MSI1 suppressed stemness and radioresistance in F‐IRR cells, whereas stable MSI1 overexpression in parental FaDu and CAL27 cells conferred enhanced stemness and radiation resistance. RNA sequencing and pathway analysis identified hyperactivation of the mitogen‐activated protein kinase (MAPK) pathway in F‐IRR cells, and targeted inhibition experiments showed that the c‐Jun N‐terminal kinase (JNK) signaling pathway was the primary upstream regulator of MSI1 expression. JNK inhibition with SP600125 reduced MSI1 levels and attenuated stemness and radioresistance in F‐IRR cells. In vivo xenograft experiments further confirmed that F‐IRR cells possessed greater tumorigenic potential and radioresistance than parental cells, with high expression of MSI1 and phospho‐JNK in tumor tissues. Collectively, these findings identify the JNK–MSI1 axis as a critical driver of CSC‐mediated radioresistance in HNSCC and a promising therapeutic target for overcoming treatment failure.Keywords: cancer stem cells, head and neck squamous cell carcinoma, Musashi‐1, radioresistance, radiotherapy Abbreviations 3′ untranslated region American Type Culture Collection basic fibroblast growth factor complementary deoxyribonucleic acid cancer stem cell 4′,6‐diamidino‐2‐phenylindole Dulbecco's Modified Eagle's Medium dimethyl sulfoxide DNA‐protein kinase catalytic subunit enhanced chemiluminescence epidermal growth factor Extreme Limiting Dilution Analysis extracellular signal‐regulated kinase fetal bovine serum FaDu irradiation‐resistant glyceraldehyde‐3‐phosphate dehydrogenase head and neck squamous cell carcinoma human papillomavirus homologous recombination immunocytochemistry ionizing radiation c‐Jun N‐terminal kinase Kyoto Encyclopedia of Genes and Genomes mitogen‐activated protein kinase Musashi‐1 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide non‐homologous end‐joining poly‐2‐hydroxyethyl methacrylate quantitative real‐time polymerase chain reaction ribonucleic acid reactive oxygen species radiotherapy reverse transcription‐polymerase chain reaction standard deviation sodium dodecyl sulfate‐polyacrylamide gel electrophoresis small interfering RNA Tris‐buffered saline with Tween‐20 Introduction Head and neck squamous cell carcinoma (HNSCC) encompasses a heterogeneous group of malignancies arising from the squamous epithelium of the oral cavity, pharynx, larynx, sinuses, and salivary glands, accounting for approximately 4% of all cancers worldwide [1, 2]. The global incidence of HNSCC continues to rise, driven primarily by tobacco use, alcohol consumption, and human papillomavirus (HPV) infection, particularly HPV‐16. Standard treatment modalities include surgery, radiotherapy (RT), chemotherapy, and immunotherapy; pembrolizumab has demonstrated efficacy in recurrent or metastatic disease [3]. Prognosis is largely determined by tumor stage, HPV status, and treatment response, with HPV‐positive tumors generally associated with more favorable outcomes. Despite the central role of RT in HNSCC management, radioresistance remains a major clinical obstacle, frequently contributing to locoregional recurrence and treatment failure. The mechanisms underlying radioresistance are multifactorial. Tumor hypoxia limits the generation of reactive oxygen species (ROS) essential for radiation‐induced DNA damage, thereby attenuating RT efficacy [4]. Upregulation of DNA repair pathways—particularly homologous recombination (HR) and non‐homologous end‐joining (NHEJ)—enables cancer cells to efficiently resolve RT‐induced DNA double‐strand breaks [5]. Cancer stem cells (CSCs) further contribute to radioresistance through heightened DNA repair capacity, cellular quiescence, and elevated antioxidant activity [6]. Dysregulation of oncogenic signaling pathways, including PI3K/AKT/mTOR and EGFR, additionally promotes cell survival and proliferation following RT [7]. Overcoming these resistance mechanisms will require integrated therapeutic strategies incorporating hypoxia‐modifying agents, DNA repair inhibitors, and molecularly targeted therapies [8, 9]. Musashi‐1 (MSI1) is a highly conserved RNA‐binding protein originally identified in neural progenitor cells and now recognized as a key regulator of CSC maintenance, self‐renewal, and asymmetric cell division across multiple malignancies, including glioblastoma, colorectal cancer, breast cancer, and HNSCC [10, 11, 12, 13, 14, 15]. MSI1 functions by binding to conserved motifs within the 3′ untranslated regions (3′ UTRs) of target mRNAs, thereby modulating their stability and translation efficiency. Its regulatory targets are enriched in transcripts governing the Notch, Wnt/β‐catenin, and Hedgehog signaling pathways, which collectively sustain CSC properties including self‐renewal, proliferation, and therapeutic resistance [16]. MSI1 also regulates genes involved in cell cycle progression, apoptosis, and differentiation [17, 18]. Critically, MSI1 has been implicated as a driver of both radioresistance and chemoresistance. Its overexpression promotes enhanced DNA damage repair, upregulation of anti‐apoptotic proteins, and maintenance of stem‐like cellular states—collectively facilitating tumor recurrence and poor clinical outcomes [10, 17, 19]. These properties position MSI1 as an attractive therapeutic target; RNA‐based therapeutics and small‐molecule inhibitors directed against MSI1 are under active investigation as strategies to resensitize tumors to existing treatments and suppress recurrence [20]. In the present study, we established a radioresistant FaDu HNSCC cell line and demonstrated that MSI1 expression is markedly elevated in these cells, identifying it as a causal determinant of the radioresistant phenotype. We further reveal that MSI1 upregulation is primarily regulated by the c‐Jun N‐terminal kinase (JNK) signaling pathway. These findings suggest that co‐targeting MSI1 and its upstream JNK‐dependent regulatory axis may represent a rational therapeutic strategy to overcome radioresistance in HNSCC. Materials and Methods Cell Lines and Culture Conditions FaDu and CAL27 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA), and SNU‐1041 cells were obtained from the Korean Cell Line Bank (Seoul, Korea). FaDu cells were maintained in Minimum Essential Medium Eagle, CAL27 cells in Dulbecco's Modified Eagle's Medium, and SNU‐1041 cells in RPMI‐1640, each supplemented with 10% fetal bovine serum (ATCC) and 1% antibiotic‐antimycotic solution (Welgene, Gyeongsan, Korea). All cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. Generation of Radioresistant FaDu Cells (F‐IRR) Radioresistant FaDu cells were established by repeated exposure to ionizing radiation (IR) at 2 Gy per fraction using a 137Cs γ‐ray source (BIOBEAM 8000; 2.6 Gy/min; Gamma‐Service Medical, Leipzig, Germany) until a cumulative dose of 30 Gy was reached. Following each irradiation session, cells were allowed to recover and re‐expand before the subsequent treatment. The establishment process was performed over a period of approximately 10 months. The surviving population was propagated and designated as FaDu‐IRR (F‐IRR). The established F‐IRR cells were used for experiments within 20 passages. Reagents and Antibodies PD98059, U0126, SP600125, SB203580, and LY294002 were purchased from Sigma‐Aldrich (St. Louis, MO, USA). Primary antibodies against MSI1 (#21534), Oct4 (#75463), LIN28B (#4196), NANOG (#4903), CD44 (#37259), SOX2 (#3579), KLF4 (#12173), phospho‐STAT3 (Tyr705; #9145), phospho‐STAT3 (Ser727; #9134), phospho‐AKT (Ser473; #9271), phospho‐AKT (Thr308; #9275), phospho‐JNK (#9251), phospho‐ERK1/2 (#4370), phospho‐p38 (#4511), phospho‐c‐Jun (Ser63; #2361), and phospho‐c‐Jun (Ser73; #3270) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against c‐Myc (sc‐40) and β‐actin (sc‐47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti‐BMI1 antibody (05–637) was obtained from Millipore (Darmstadt, Germany). siRNA Transfection and MSI1 Overexpression siRNA‐mediated knockdown of MSI1 was performed using two independent siRNA sequences (siMSI1 #1: sense 5′‐AUAAUCUUUGUUACUGAGAUGCGCG‐3′, antisense 5′‐CGCGCAUCUCAGUAACAAAGAUUAUUG‐3′; siMSI1 #3: sense 5′‐CACCAAUGGGUACCACUGAAGCAGG‐3′, antisense 5′‐CCUGCUUCAGUGGUACCCAUUGGUGAA‐3′; Integrated DNA Technologies, Coralville, IA, USA) using INTERFERin transfection reagent (Polyplus, Illkirch, France) according to the manufacturer's protocol. For MSI1 overexpression, the pGFP‐C‐shLenti and pGFP‐C‐shLenti MSI1 vectors (OriGene, #NM_002442, Rockville, MD, USA) were used. Lentiviral particles were produced by co‐transfecting 293 T cells with the lentiviral vector along with psPAX2 packaging and pMD2.G envelope plasmids. Viral supernatants were collected 48 h post‐transfection, filtered, and concentrated using the Lenti‐X Concentrator (#PT4421‐2; Takara, Kusatsu, Japan). Western Blot Analysis Cells were lysed in RIPA buffer (50 mM Tris–HCl [pH 7.4], 100 mM NaCl, 5 mM EDTA, 0.5% Nonidet P‐40) supplemented with protease and phosphatase inhibitors. Protein concentrations were determined by Bradford assay (Bio‐Rad, Hercules, CA, USA). Equal amounts of protein were separated by SDS‐PAGE (10%–15%) and transferred onto nitrocellulose membranes. Membranes were blocked with 5% skim milk in TBST for 1 h at room temperature and incubated with primary antibodies overnight at 4°C. After washing, membranes were incubated with horseradish peroxidase‐conjugated secondary antibodies at room temperature. Proteins were visualized using enhanced chemiluminescence (ECL) reagents according to the manufacturer's instructions. RNA Extraction, Reverse Transcription‐PCR (RT‐PCR) and Quantitative Real‐Time PCR (qPCR) Total RNA was extracted using TRIsure reagent (Bioline, London, UK) according to the manufacturer's instructions. First‐strand cDNA synthesis was performed using a reverse transcription kit (Bioline). Conventional RT‐PCR was performed using MyTaq Red Mix (BIOLINE) and qPCR was carried out using the SensiFAST SYBR No‐ROX Kit (BIOLINE). Gene expression levels were normalized to GAPDH. Primer sequences used were as follows: MSI1 (forward: 5′‐TCTCGAGTCATGCCCTACG‐3′; reverse: 5′‐GGTCCGCTCTACACGGAAT‐3′) and Oct4 (forward: 5′‐GGATTAAGTTCTTCATTCACTAAG‐3′; reverse: 5′‐TAAGTGTGTCTATCTACTGTGTCC‐3′). RNA Sequencing and Data Analysis Ribonucleic acid sequencing and primary data processing were performed by Ebiogen (Seoul, Korea). Differential gene expression analysis was conducted using ExDEGA and ExDEGA GraphicPlus software (Ebiogen). Gene expression profiles were compared between FaDu and F‐IRR cells, and pathway enrichment analysis was performed using KEGG annotations. Immunocytochemistry (ICC) Cells (3 × 104) were seeded on coverslips and fixed with 4% paraformaldehyde, followed by permeabilization with 0.1% Triton X‐100. After blocking, cells were incubated with the indicated primary antibodies overnight at 4°C, followed by incubation with Alexa Fluor 594‐ or Alexa Fluor 488‐conjugated anti‐rabbit secondary antibodies (Bethyl Laboratories, Montgomery, TX, USA). Nuclei were counterstained with DAPI (Sigma‐Aldrich). Fluorescence images were acquired using an Olympus IX53 fluorescence microscope (Tokyo, Japan), and signal intensity was quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Cell Viability Assay Cell viability was assessed by MTT assay. Briefly, cells (2.5 × 103 per well) were seeded in 96‐well plates and incubated with MTT solution (0.8 mg/mL) for 3 h at 37°C. The resulting formazan crystals were dissolved in dimethyl sulfoxide (DMSO; Duchefa Biochemistry, Haarlem, the Netherlands), and absorbance was measured at 490 nm using a microplate reader (Bio‐Rad). Clonogenic Survival Assay Cells (3 × 103 per well) were seeded in 6‐well plates and allowed to adhere overnight. Cells were then exposed to γ‐irradiation at doses of 1, 3, 5, or 7 Gy using a 137Cs γ‐ray source (BIOBEAM 8000; 2.6 Gy/min; Gamma‐Service Medical). After 7–14 days, colonies were fixed and stained with 0.05% crystal violet in 20% methanol. Visible colonies (≥ 50 cells) were counted. Sphere Formation and Limiting Dilution Assays Self‐renewal capacity was assessed by sphere formation and limiting dilution assays using poly‐2‐hydroxyethyl methacrylate (poly‐HEMA)‐coated plates. Cells were cultured in serum‐free DMEM/F12 medium (Invitrogen, Carlsbad, CA, USA) supplemented with epidermal growth factor (20 ng/mL), basic fibroblast growth factor (20 ng/mL), and B27 supplement (1:50 dilution). After 5–7 days, spheres were visualized and quantified using an ECLIPSE TS100 microscope (Nikon, Tokyo, Japan). For sphere‐forming assays, only compact and round spheroids with a diameter of ≥ 100 μm were counted as spheres. Smaller cell aggregates or irregular clusters were excluded from the analysis. The same cutoff criterion was applied consistently across all experimental groups. Limiting dilution analysis was performed using the Extreme Limiting Dilution Analysis (ELDA) web tool [20]. Soft Agar Assay Anchorage‐independent growth was evaluated by soft agar assay. A base layer of 1% agar in DMEM/F12 was prepared in six‐well plates. Single‐cell suspensions were mixed with 0.7% agar in DMEM/F12 containing 10% FBS and overlaid onto the solidified base layer. Cells were cultured under standard conditions for 2–3 weeks, after which colonies were visualized using an ECLIPSE TS100 microscope (Nikon). For soft agar assays, colonies were counted only when they formed compact, clearly distinguishable colonies with a diameter of ≥ 100 μm. Small cell aggregates or irregular clusters were excluded from the analysis. The same cutoff criterion was applied consistently across all experimental groups. In Vivo Xenograft Study All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences (KIRAMS). Female BALB/c nude mice (4 weeks old, 17–20 g) were obtained from JA BIO (Suwon, Korea). FaDu or F‐IRR cells (2.5 × 106) were resuspended in a 1:1 mixture of culture medium and Matrigel (#354234; Corning, Corning, NY, USA) and subcutaneously inoculated into the right flank. Once tumors reached an appropriate volume, mice were randomly allocated to experimental groups (n = 6 per group) and irradiated with a single dose of 6 Gy using an X‐ray unit (260 kVp, 10 mA; 2 mm copper filtration; dose rate: 2 Gy/min; source‐to‐target distance: 41 cm). Tumor dimensions were measured using calipers, and tumor volume was calculated as (length × width2) × 0.5. Body weights were monitored throughout the experiment, and no significant weight loss (> 10%) was observed in any group. Immunohistochemistry Tumor tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (4 μm thick) were prepared using a microtome and immunostained with antibodies against MSI1, phospho‐JNK, γ‐H2AX, and Ki‐67. Fluorescently labeled secondary antibodies conjugated with DyLight 488 or DyLight 594 (1:100; Bethyl Laboratories) were applied. Sections were visualized using an Olympus IX53 fluorescence microscope, and signal intensity was quantified using ImageJ software. Statistical Analysis All data are presented as mean ± standard deviation (SD) from at least three independent experiments. Statistical significance was determined using Student's t‐test. A p < 0.05 was considered statistically significant and denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. Significance levels indicate comparisons only between the groups connected by brackets. Statistical analyses and data visualization were performed using Microsoft Excel and GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA), and the Extreme Limiting Dilution Analysis (ELDA) web tool. Results F‐IRR Cells Exhibit Enhanced Stemness and Elevated MSI1 Expression To investigate the mechanisms of radioresistance in HNSCC, we established an IR‐resistant FaDu cell line, designated F‐IRR, by subjecting parental FaDu cells to repeated fractionated IR (2 Gy × 15 fractions; cumulative dose 30 Gy; Figure 1A). Radioresistance of the established F‐IRR cells was confirmed by clonogenic survival assay following IR treatment (Figure 1B). Although F‐IRR cells exhibited a slower proliferation rate than parental cells in the MTT assay (Figure 1C), sphere‐forming and limiting dilution assays demonstrated significantly enhanced stemness in F‐IRR cells (Figure 1D,E). Consistent with these observations, F‐IRR cells displayed markedly increased anchorage‐independent growth, as assessed by soft agar colony‐forming assay (Figure 1F). Western blot analysis revealed elevated expression of MSI1, OCT4, and CD44 in F‐IRR cells compared with parental cells (Figure 1G). Elevated MSI1 and OCT4 expression in F‐IRR cells was further confirmed by RT‐PCR and ICC (Figure 1H,I). Given its well‐established role in CSC biology and therapeutic resistance, subsequent studies focused on elucidating the functional role of MSI1. Radioresistant FaDu cells (F‐IRR) exhibit cancer stem cell properties and elevated MSI1 expression. (A) Schematic showing the generation of F‐IRR cells by repeated fractionated IR (2 Gy × 15 fractions; cumulative dose 30 Gy) over a period of 10 months to generate radioresistant cells (F‐IRR). (B) Clonogenic survival assay of FaDu and F‐IRR cells after IR. Cells (3 × 103) were irradiated at the indicated doses and cultured for 7 days. (C) Cell viability measured by MTT assay at the indicated time points. (D) Sphere formation and (E) limiting dilution assays assessing self‐renewal capacity. (F) Soft agar colony formation assay evaluating anchorage‐independent growth. (G) Western blot analysis of stemness‐associated protein expression. (H) RT‐PCR (left) and qPCR (right) analysis of MSI1 and Oct4 mRNA expression. (I) ICC of MSI1 (upper) and Oct4 (lower). Nuclei were counterstained with DAPI (blue). Data are presented as mean ± SD. **p < 0.01, ***p < 0.001. MSI1 Knockdown Suppresses Radioresistance, Stemness, and Tumorigenic Potential in F‐IRR Cells To determine whether MSI1 expression functionally contributes to the IR‐resistant phenotype, we performed loss‐of‐function experiments by transfecting F‐IRR cells with MSI1‐targeting siRNA (siMSI1). Successful knockdown was confirmed by western blot, RT‐PCR, and ICC (Figure 2A,B). siMSI1 transfection significantly inhibited cell growth (Figure 2C) and reduced stemness, as evidenced by sphere‐forming and limiting dilution assays (Figure 2D,E). Anchorage‐independent growth was similarly diminished (Figure 2F). Importantly, siMSI1 significantly suppressed radioresistance in IR colony‐forming assays (Figure 2G). Knockdown of MSI1 inhibits radioresistance and cancer stem cell properties in F‐IRR cells. (A) Western blot (upper) and RT‐PCR (lower) analyses confirming siRNA‐mediated knockdown of MSI1 in F‐IRR cells. (B) ICC of MSI1 (red) in F‐IRR cells following siRNA‐mediated knockdown. Nuclei were counterstained with DAPI (blue). (C) MTT, (D) sphere formation, (E) limiting dilution, (F) soft agar colony formation, and (G) clonogenic survival assays of F‐IRR cells following siRNA‐mediated knockdown of MSI1. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. To assess whether these effects extended beyond the F‐IRR model, siMSI1 was transfected into SNU‐1041 cells, which exhibit higher baseline MSI1 expression and radioresistance compared with FaDu cells (Figure S1A,B). Consistent with findings in F‐IRR cells, siMSI1 transfection (Figure S1C) significantly reduced stemness (Figure S1D) and radioresistance in SNU‐1041 cells (Figure S1E). Collectively, these results indicate that elevated MSI1 expression functionally contributes to IR resistance, stemness, and tumorigenic potential in HNSCC cells. MSI1 Overexpression Confers Radioresistance and Enhanced Stemness in Parental FaDu Cells To further validate the functional role of MSI1, gain‐of‐function experiments were performed by stably overexpressing MSI1 in parental FaDu cells. Overexpression was confirmed by western blot, RT‐PCR, and ICC (Figure 3A,B). MSI1 overexpression promoted cell growth (Figure 3C), enhanced stemness as assessed by sphere‐forming and limiting dilution assays (Figure 3D,E), and increased both anchorage‐independent growth and radioresistance (Figure 3F,G). Enforced MSI1 expression promotes radioresistance and cancer stem cell properties in parental FaDu cells. (A) Western blot (upper) and RT‐PCR (lower) analyses confirming MSI1 overexpression in FaDu cells. (B) ICC of MSI1 (red). Nuclei were counterstained with DAPI (blue). (C) MTT, (D) sphere formation, (E) limiting dilution, (F) soft agar colony formation, and (G) clonogenic survival assays of FaDu cells following MSI1 overexpression. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001. To corroborate these findings in an independent cellular context, MSI1 was overexpressed in CAL27 cells (Figure S2A), which express markedly lower baseline levels of MSI1 than FaDu cells (Figure S1A). MSI1 overexpression similarly increased stemness and radioresistance in CAL27 cells (Figure S2B,C). Taken together, these gain‐ and loss‐of‐function data establish MSI1 as a functional driver of radioresistance and stemness in HNSCC. JNK Signaling Hyperactivation Drives Elevated MSI1 Expression in F‐IRR Cells To identify the upstream signaling mechanisms regulating MSI1 expression in F‐IRR cells, we performed RNA sequencing on parental FaDu and F‐IRR cells. KEGG pathway enrichment analysis revealed significant upregulation of the mitogen‐activated protein kinase (MAPK) signaling pathway in F‐IRR cells (Figure 4A). Western blot analysis confirmed increased phosphorylation of AKT, ERK1/2, JNK, and p38 MAPK in F‐IRR cells relative to parental cells (Figure 4B). Subsequent treatment with specific pharmacological inhibitors targeting each kinase demonstrated that the JNK inhibitor SP600125 most markedly reduced MSI1 expression at both mRNA and protein levels (Figure 4C,D), which was further confirmed by ICC (Figure 4E). SP600125 treatment also attenuated cell growth in the MTT assay (Figure 4F), and stemness in sphere‐forming and limiting dilution assays, reduced anchorage‐independent growth, and decreased radioresistance in F‐IRR cells (Figure 4G–J). These findings indicate that hyperactivation of JNK signaling is the primary upstream regulator of MSI1 expression, stemness, and radioresistance in F‐IRR cells. Hyperactivation of the JNK/c‐Jun pathway drives MSI1 expression in F‐IRR cells. (A) KEGG pathway enrichment analysis in F‐IRR cells. (B) Western blot analysis of MAPK‐related signaling proteins. (C) Western blot analysis of F‐IRR cells treated with MAPK pathway inhibitors for 48 h. (D) Western blot (upper) and RT‐PCR (lower) analyses showing the effects of SP600125 treatment (48 h) on phospho‐JNK, phospho‐c‐Jun, and MSI1 expression. (E) ICC of phospho‐JNK (green) and MSI1 (red) in FaDu and F‐IRR cells treated with or without SP600125 for 48 h. Nuclei were counterstained with DAPI (blue). (F) MTT, (G) sphere formation, (H) limiting dilution, (I) soft agar colony formation, and (J) clonogenic survival assays showing reduced growth, stemness, anchorage‐independent growth and radioresistance of F‐IRR cells following SP600125 treatment. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001. F‐IRR Cells Exhibit Enhanced Tumor Formation and Radioresistance in Vivo To evaluate the in vivo relevance of our findings, the tumor‐forming ability and radiation response of F‐IRR cells were assessed in a murine xenograft model. Although initial tumor engraftment was slower in mice implanted with F‐IRR cells than in those receiving parental FaDu cells (Figure 5A), post‐irradiation F‐IRR tumors exhibited a more rapid initial growth rate than their non‐irradiated counterparts, with no significant differences in final tumor size or volume between the two F‐IRR groups (Figure 5B–D). Immunohistochemical analysis of tumor tissues confirmed high‐level expression of MSI1 and phospho‐JNK, along with reduced expression of the proliferation marker Ki‐67 and the DNA damage marker γ‐H2AX, in F‐IRR tumors relative to parental FaDu tumors (Figure 5E). These in vivo data corroborate our in vitro findings and support the conclusion that the JNK–MSI1 signaling axis contributes to the radioresistant phenotype of F‐IRR cells. MSI1 confers radioresistance in vivo. (A) Tumor growth curves of xenografts derived from FaDu, FaDu + IR, F‐IRR, and F‐IRR + IR groups (n = 6 per group). IR was performed at a dose of 6 Gy. (B) Tumor weight at the experimental endpoint (n = 6). (C) Ratio of tumor weight to body weight (n = 6). (D) Representative images of xenograft tumors from each group. (E) ICC of MSI1 (red), phospho‐JNK (green), Ki‐67 (green), and γ‐H2AX (red) in tumor sections from each group. Nuclei were counterstained with DAPI (blue). Quantification of fluorescence intensity is shown on the right. Data are presented as mean ± SD. **p < 0.01, ***p < 0.001. Discussion Radiotherapy is a cornerstone of HNSCC treatment; however, its efficacy is frequently compromised by radioresistance, which is closely associated with CSCs [21]. CSCs are inherently refractory to radiation owing to robust DNA repair capacity, efficient antioxidant systems, and altered cell cycle regulation, which collectively contribute to tumor recurrence [22, 23, 24, 25]. Key molecular determinants of this radioresistant phenotype include activation of the Wnt/β‐catenin, Notch, and Hedgehog signaling pathways; overexpression of the transcription factors OCT4, SOX2, and NANOG; and surface expression of markers such as CD133 and CD44 [26, 27, 28]. Elucidating the molecular mechanisms linking CSC properties to radioresistance is therefore critical for developing novel therapeutic strategies to improve clinical outcomes in HNSCC [29]. In the present study, we established a radiation‐resistant HNSCC cell line (F‐IRR) from parental FaDu cells and demonstrated that F‐IRR cells exhibit markedly enhanced CSC activity accompanied by significantly elevated expression of multiple stem cell‐associated factors. Among these, MSI1 was selected for detailed functional investigation, and a series of complementary gain‐ and loss‐of‐function experiments collectively established MSI1 as a critical determinant of radioresistance in HNSCC. These findings suggest that therapeutic strategies targeting MSI1 represent a promising avenue for enhancing the efficacy of RT in this disease. MSI1 has emerged as an important mediator of radiation resistance across multiple cancer types. Elevated MSI1 expression is frequently associated with enhanced stem cell‐like properties and increased survival following radiation exposure [17, 18, 30, 31]. This resistance has been attributed to the involvement of MSI1 in critical cellular processes, including DNA damage repair via NHEJ and HR, which enable cancer cells to efficiently resolve radiation‐induced DNA double‐strand breaks [18, 32]. In glioblastoma, MSI1 promotes cell survival following irradiation by enhancing DNA damage repair, potentially through stabilization of the DNA‐protein kinase catalytic subunit (DNA‐PKcs) [30]. MSI1 also modulates cell cycle progression and apoptosis, thereby indirectly contributing to radioresistance by sustaining cancer cell proliferation and attenuating radiation‐induced cell death [33]. Our data from F‐IRR cells and additional HNSCC cell lines are consistent with these reports and further support the notion that targeting MSI1 or its downstream effectors represents a rational strategy for overcoming radioresistance in HNSCC. JNKs are stress‐activated protein kinases with complex, context‐dependent roles in cancer, including regulation of CSC biology and therapeutic resistance [34, 35]. Although JNK activation is classically associated with pro‐apoptotic responses, dysregulated JNK signaling in CSCs can paradoxically promote cell survival and therapy resistance. For instance, JNK signaling confers chemoresistance in pancreatic CSCs by attenuating chemotherapy‐induced ROS accumulation [36], and JNK inhibition sensitizes metastatic tetraploid cancer cells to irradiation‐induced apoptosis [37]. In the present study, F‐IRR cells displayed markedly elevated JNK activity relative to parental cells, and this hyperactivated JNK signaling was identified as the primary upstream driver of MSI1 overexpression, enhanced stemness, and radioresistance. These findings define a JNK–MSI1 regulatory axis that sustains CSC properties and radiation resistance in HNSCC, and suggest that co‐targeting this pathway may represent an effective radiosensitization strategy. Notably, although F‐IRR cells proliferated more slowly than parental FaDu cells under standard culture conditions, they exhibited markedly superior sphere‐forming capacity, anchorage‐independent growth, and in vivo tumorigenic potential. This apparent paradox is consistent with established characteristics of CSC‐enriched populations, which prioritize self‐renewal and stress resistance over rapid proliferation. The slower in vivo engraftment of F‐IRR tumors, followed by sustained growth and pronounced radioresistance, further supports the notion that the F‐IRR model recapitulates clinically relevant features of treatment‐refractory HNSCC. Although F‐IRR cells exhibited elevated MSI1 expression, they showed relatively delayed growth compared with parental cells, whereas MSI1‐overexpressing cells displayed enhanced growth. This apparent discrepancy may be explained by the distinct biological nature of these two experimental models. Previous studies have shown that MSI1 promotes cancer cell proliferation and tumor‐related phenotypes in prostate cancer and neuroblastoma, supporting the growth‐promoting effect observed in our MSI1‐overexpressing cells [38, 39]. In contrast, F‐IRR cells were generated through repeated fractionated irradiation and therefore represent a complex acquired radioresistant model rather than a simple MSI1‐overexpression system. Consistent with this interpretation, acquired radioresistant cancer cell lines have been reported to exhibit altered growth characteristics, including slower growth, possibly reflecting irradiation‐induced adaptive changes such as clonal selection, chronic stress responses, DNA damage response alterations, and cell‐cycle changes [40]. Thus, the delayed growth of F‐IRR cells may result from additional adaptive changes acquired during the establishment of radioresistance, whereas MSI1 appears to contribute primarily to the maintenance of stemness and radioresistant phenotypes. In conclusion, the present study demonstrates that HNSCC cells can acquire enhanced stemness and radioresistance through MSI1 overexpression driven by activated JNK signaling. A schematic diagram summarizing the main findings of this study is shown in Figure 6. The F‐IRR cell model established here provides a tractable experimental platform for investigating the molecular mechanisms of radioresistance. These findings highlight the JNK–MSI1 signaling axis as a potential therapeutic target, and further development of radiosensitization strategies directed at this pathway—including pharmacological JNK inhibitors and MSI1‐targeting agents—warrants investigation in preclinical and clinical settings. Graphical abstract of JNK–MSI1‐mediated stemness and radioresistance in HNSCC. Radioresistant F‐IRR cells were established from parental FaDu cells by repeated fractionated irradiation (2 Gy × 15 fractions; total dose, 30 Gy), and their radioresistant phenotype was confirmed by clonogenic assay. Despite slower proliferation, F‐IRR cells exhibited enhanced cancer stem cell properties, including increased sphere formation, self‐renewal, and anchorage‐independent growth, accompanied by elevated MSI1 expression. Activation of JNK signaling increased MSI1 expression and promoted stemness, tumorigenicity, and radioresistance. Inhibition of JNK with SP600125 reduced MSI1 expression and attenuated these phenotypes. In vivo subcutaneous xenograft experiments further demonstrated enhanced radioresistance of F‐IRR tumors, together with high MSI1 and phospho‐JNK expression. Author Contributions Na‐Eun Kang: conceptualization, data curation, investigation, validation, visualization, writing – original draft. Chan‐Woong Jung: conceptualization, data curation, investigation, validation, visualization. Yun‐Ju Kim: data curation. Sung‐Gil Chi: project administration. Jeong‐Yub Kim: conceptualization, formal analysis, project administration, supervision. Myung‐Jin Park: conceptualization, project administration, writing – review and editing, funding acquisition. Funding This work was supported by the Ministry of Science and ICT, South Korea, grant no. 50531‐2026, grant no. RS‐2022‐NR072416. Ethics Statement Animal Studies: All animal experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Korea Institute of Radiological and Medical Sciences (protocol No. 2025‐0117). Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Knockdown of MSI1 inhibits radioresistance and cancer stem cell properties in SNU‐1041 cells. (A) Western blot analyses of MSI1 expression in HNSCC cell lines. (B) Clonogenic survival assay of HNSCC cell lines after radiation exposure. (C) Western blot (left) and RT‐PCR (right) analyses confirming siRNA‐mediated knockdown of MSI1 in SNU‐1041 cells. (D) Limiting dilution and (E) Clonogenic survival assays of SNU‐1041 cells following siRNA‐mediated knockdown of MSI1 in SNU‐1041 cells. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Figure S2: Enforced MSI1 expression promotes radioresistance and cancer stem cell properties in CAL27 cells. (A) Western blot (left) and RT‐PCR (right) analyses confirming MSI1 overexpression in CAL27 cells. (B) Limiting dilution and (C) clonogenic survival assays of CAL27 cells following MSI1 overexpression. Data are presented as mean ± SD. *p < 0.05, **p < 0.01. Acknowledgments The authors have nothing to report. Contributor Information Jeong‐Yub Kim, Email: wjdduql@hanmail.net. Myung‐Jin Park, Email: mjpark1650@gmail.com. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Figure S1: Knockdown of MSI1 inhibits radioresistance and cancer stem cell properties in SNU‐1041 cells. (A) Western blot analyses of MSI1 expression in HNSCC cell lines. (B) Clonogenic survival assay of HNSCC cell lines after radiation exposure. (C) Western blot (left) and RT‐PCR (right) analyses confirming siRNA‐mediated knockdown of MSI1 in SNU‐1041 cells. (D) Limiting dilution and (E) Clonogenic survival assays of SNU‐1041 cells following siRNA‐mediated knockdown of MSI1 in SNU‐1041 cells. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Figure S2: Enforced MSI1 expression promotes radioresistance and cancer stem cell properties in CAL27 cells. (A) Western blot (left) and RT‐PCR (right) analyses confirming MSI1 overexpression in CAL27 cells. (B) Limiting dilution and (C) clonogenic survival assays of CAL27 cells following MSI1 overexpression. Data are presented as mean ± SD. *p < 0.05, **p < 0.01. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.